Mesoblast (ASX:MSB) announced that the U.S. FDA acknowledged that clinical trial data demonstrate meaningful and sustained reductions in chronic low back pain, with the potential to reduce accompanying opioid use.

Neurizon Therapeutics (ASX:NUZ) has announced the successful registration of its NEURIZON trademark across all major pharmaceutical markets.

AusBiotech has been named as one of the national peak bodies selected to join the Australian Government’s newly established Trade Diversification Network.

HaemaLogiX has appointed Dr Chris Baldwin as Chief Executive Officer and Managing Director, marking a significant leadership transition as the company prepares for its next stage of clinical and corporate development.

Neuren Pharmaceuticals (ASX:NEU) has entered 2026 with growing confidence in the global trajectory of DAYBUE, its first-in-class treatment for Rett syndrome, as new data and commercial milestones continue to accumulate.

Australian radiopharmaceutical company Cyclopharm (ASX:CYC) has achieved a significant milestone in its US expansion, with Lucile Packard Children’s Hospital Stanford set to implement Technegas for paediatric lung imaging.

Dimerix (ASX:DXB) has found itself at the centre of a significant global rare-disease transaction, following BioMarin Pharmaceutical’s US$4.8 billion acquisition of Amicus Therapeutics, the Australian company’s U.S. commercial licensing partner.

Clarity Pharmaceuticals (ASX:CU6) has taken a step toward regulatory approval of its diagnostic imaging agent, announcing it will commence a pivotal Phase 3 trial of Cu-64 SARTATE in patients with neuroendocrine tumours following positive guidance from the U.S. Food and Drug Administration.

Telix Pharmaceuticals (ASX:TLX) has delivered a significant advance in its global precision medicine strategy, announcing positive topline results from a pivotal Phase 3 registration study of TLX591-CDx (ILLUCCIX) in Chinese patients with prostate cancer.

INOVIQ (ASX:IIQ) has reported preclinical evidence supporting the potential of its chimeric antigen receptor exosome technology as a next-generation cancer therapeutic.

Neuren Pharmaceuticals (ASX:NEU) has reached a regulatory milestone with Health Canada approving its Clinical Trial Application for the Koala Phase 3 clinical trial of NNZ-2591, a drug candidate under development for Phelan-McDermid syndrome.

A new antimalarial drug candidate developed through a long-running collaboration between Melbourne’s WEHI and MSD is showing promise in the fight against malaria, particularly as resistance to existing treatments continues to spread.

Australian medtech company Ferronova has raised a further $6 million to support the commercialisation of its image-guided cancer surgery technology.

Actinogen Medical (ASX:ACW) has hit a significant milestone in its push to bring a new oral Alzheimer’s therapy to market, completing enrolment in its pivotal XanaMIA trial and confirming November 2026 for topline results.

Island Pharmaceuticals (ASX:ILA) has taken a step forward in the development of its antiviral candidate galidesivir, securing a strategic partnership with the Texas Biomedical Research Institute, one of the world’s most advanced infectious disease centres and a critical player in high-containment pathogen research.

Cleo Diagnostics (ASX:COV) has secured $5 million in capital to support its expansion into the United States and speed the development of a new mass screening test for ovarian cancer, in a raise that attracted strong backing from institutional and high-net-worth investors.

OncoSil Medical (ASX:OSL) has marked a significant milestone in its manufacturing strategy, announcing the successful completion of the first 'hot' production test run at its new Sydney facility.